Cyto Biotech: Announcement on returning idle raised funds to replenish working capital
Securities code: 300583 Securities abbreviation: Cyto Biotechnology Announcement number: 2026-016
Shandong Saito Biotechnology Co., Ltd.
Announcement on returning idle raised funds to supplement working capital
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Shandong Saito Biotechnology Co., Ltd. (hereinafter referred to as the "Company") held the 8th meeting of the 4th Board of Directors and the 8th meeting of the 4th Board of Supervisors on April 25, 2025, and reviewed and approved the "Proposal on the Company and its wholly-owned subsidiaries using part of the idle raised funds to temporarily supplement working capital", and agreed that the company and its wholly-owned subsidiaries will use part of the idle raised funds to temporarily supplement working capital on the premise of ensuring the capital needs for the construction of investment projects with raised funds. The total amount shall not exceed 15,000.00. Ten thousand yuan, the use period shall not exceed twelve months from the date of review and approval by the board of directors, and will be returned to the special account for raised funds upon expiration. For details, please refer to the "Announcement on the Company and its wholly-owned subsidiaries using part of the idle raised funds to temporarily supplement working capital" disclosed by the company on cninfo.com on April 29, 2025 (announcement number: 2025-016).
On December 30, 2025, the company returned RMB 50 million of the above-mentioned raised funds to temporarily supplement working capital in advance to the special account for raised funds. For details, please refer to the "Announcement on Returning Part of Idle Raised Funds to Supplement Working Capital" disclosed by the company on cninfo.com (announcement number: 2025-050).
On April 21, 2026, the company returned 100 million yuan of the above-mentioned raised funds to temporarily supplement working capital to the special account for raised funds, and notified the company's sponsor and sponsor representative of the return of the above-mentioned raised funds. So far, the company has used part of the idle raised funds to temporarily supplement working capital and has all returned it.
Announcement is hereby made.
Board of Directors of Shandong Saito Biotechnology Co., Ltd.
April 21, 2026